Covid-19 threatens biopharma in-house manufacturing – GlobalData

The outbreak of Covid-19 threatens biopharmaceutical in-house manufacturing in China, says GlobalData, which could seriously impact the availability of drugs made and marketed in the UK.

The data and analytics company says that Covid-19 is putting the complicated global biopharma industry’s supply chain under strain.

In China, supply chain problems include a largely quarantined workforce, delays in transporting materials and several other logistical hurdles.

While some Chinese factories have returned to normal capacity, others are reportedly operating at between 50% and 80% capacity.

As a result, the ongoing pandemic may affect drugs made and marketed by mega cap biopharma companies such as the UK-based AstraZeneca and Switzerland-based Novartis and Roche.

Fiona Barry, Associate Editor of PharmSource at GlobalData, says: “Restrictions on pharmaceutical manufacturing and export will affect many products sold in the US, EU, and other markets. Some of these drugs are manufactured in-house at the biopharma companies’ Chinese manufacturing sites—also known as ‘captive capacity’ manufacturing—while others are outsourced to contract manufacturing organizations (CMOs) with facilities in China.”

Affected drugs include AstraZeneca’s Plendil (felodipine), marketed for angina, whose finished dose form is manufactured in-house at AstraZeneca’s site in Wuxi, Jiangsu, China, and Pfizer’s antidepressant Zoloft (sertraline hydrochloride), whose dose form manufacture and packaging are performed at Pfizer’s site in Dalian, Liaoning, China.

However, this does not mean manufacture of these drugs is completely halted. Several biopharma companies dual-source their manufacturing. For instance, the dose form of AstraZeneca’s Plendil is also manufactured at the company’s Stockholm, Sweden site, and Zoloft is manufactured at several sites outside China by Pfizer and by CMOs.

“It is unclear to what extent disruption in China will affect the world’s supply of pharmaceuticals, as other regions are increasing their production,” said Ms Barry.

“The Government of India has announced US$1.96bn boost to domestic active pharmaceutical ingredient manufacturing driven by the Covid-19 pandemic’s effect on Chinese supply chains.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...